Editor’s note: The approvals are listed from most to least recent.
- Biogen’s Aduhelm — The first treatment approved by the FDA to slow cognitive decline from Alzheimer’s disease and the first new Alzheimer’s drug approved in nearly two decades.
- Novo Nordisk’s Wegovy — An injectable drug designed for chronic weight management in adults with obesity.
- ProMetic Biotherapeutics’ Ryplazim — A drug designed to treat patients with plasminogen deficiency type 1, also called hypoplasminogenemia, a disorder that can impair normal tissue and organ function and that may lead to blindness.
- Amgen’s Lumakras — The first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.
- Johnson & Johnson’s Rybrevant — The first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations.
- AstraZeneca’s Farxiga — Oral tablets intended to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
